Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03286335 · ClinicalTrials.gov registry record · NA

Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy

A NA study of Brain Tumor, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT03286335 is a NA study of Brain Tumor that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 280-participant average among 69 other Brain Tumor trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03286335, a NA study of Brain Tumor, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This research study is studying Proton Radiation as a possible treatment for brain tumor. The radiation involved in this study is: -Proton Radiation

Conditions Studied

Interventions

  • RADIATION Proton Radiation

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2018-09-26
Est. Completion 2027-09-30
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT03286335

The ClinicalTrials.gov registry entry for NCT03286335 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 69 other Brain Tumor trials with a reported enrollment target (64% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which Proton Radiation is the first listed.

NCT03286335 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03286335 about?

NCT03286335 is a clinical study titled "Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy". This research study is studying Proton Radiation as a possible treatment for brain tumor. The radiation involved in this study is: -Proton Radiation

What is the current status of trial NCT03286335?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2018-09-26. Estimated completion is 2027-09-30.

What conditions does trial NCT03286335 study?

This clinical trial studies the following conditions: Brain Tumor.

What interventions are being tested in trial NCT03286335?

The interventions under investigation include: Proton Radiation (RADIATION).

Who is sponsoring clinical trial NCT03286335?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03286335 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.